Beatrix Bálint - Concepedia

Author

Beatrix Bálint

University of Szeged

Also Known As

B Balint, B Bálint, B. Balint, B. Bálint, Balint, Beatrix, Beatrix Balint, Beatrix Bálint, Theodoros Kontakiotis

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of Szeged Poznan University of Medical Sciences Eli Lilly (Germany)The Christie Hospital Eötvös Loránd University

About

Beatrix Bálint is an author at University of Szeged specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.4K
2	Allergy	4	4	102
3	Engineering	2	2	56
4	Health Sciences	2	2	494
5	Business	1	1	27

Beatrix Bálint

Publications

Citations

H-Index

Page 1

	Year	Citations
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Nick Thatcher, Fred R. Hirsch, Alexander Luft, The Lancet Oncology First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCisplatin Versus Gemcitabine	2015	472
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Journal of Clinical Oncology Cp ChemotherapyMedicinePhase IiiPharmacologyClinical Trials	2010	453
Increased Leukotrienes in Exhaled Breath Condensate in Childhood Asthma Zsuzsanna Csoma, Sergei A. Kharitonov, Beatrix Bálint, American Journal of Respiratory and Critical Care Medicine	2002	199
Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke Beatrix Bálint Thorax	2001	147
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu, The Lancet Oncology First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCancer Treatment	2015	129
Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis Beatrix Bálint, Sergei A. Kharitonov, Tomohiro Hanazawa, European Respiratory Journal	2001	117
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD A. Kirsten, Karin Förster, E. Radeczky, Pulmonary Pharmacology & Therapeutics Advanced Lung DiseasePulmonary PharmacologyPulmonary MedicinePharmacotherapySelective Cxcr2 Antagonist	2015	86
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Luis Paz‐Ares, Beatrix Bálint, Richard H. De Boer, Journal of Thoracic Oncology Randomized Phase 2MedicinePharmacologyPathologyImmune Checkpoint Inhibitor	2013	71
Fluticasone/Formoterol Combination Therapy versus Budesonide/Formoterol for the Treatment of Asthma: A Randomized, Controlled, Non-Inferiority Trial of Efficacy and Safety Anna Bodzenta‐Łukaszyk, Roland Buhl, Beatrix Bálint, Journal of Asthma	2012	53
Nitric Oxide Metabolites Are Not Reduced in Exhaled Breath Condensate of Patients With Primary Ciliary Dyskinesia* Zsuzsanna Csoma, Andrew Bush, Nicola Wilson, CHEST Journal Lung InflammationPhysiologyPulmonary PharmacologyPulmonary MedicineExhaled Breath Condensate	2003	51

Page 1